Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden

Table 1 HRs (95% CIs) for recurrent VTE after the cessation of anticoagulation for the index VTE by duration of use in men diagnosed with prostate cancer between 2007 and 2016 and followed until December 31, 2017, and registered in the NPCR of Sweden

Duration of anticoagulant therapy	DVT			PE			VTE^*
	Incident cases/person-years	Crude RR (95% CI)	Adjusted RR^† (95% CI)	Incident cases/person-years	Crude RR (95% CI)	Adjusted RR^† (95% CI)	Incident cases/person-years	Crude RR (95% CI)	Adjusted RR^† (95% CI)
≤ 3 months N = 102	11/68	1.00	1.00	5/13	1.00	1.00	17^†/88	1.00	1.00
> 3 to 6 months N = 127	9/75	0.74 (0.31–1.79)	0.71 (0.29–1.74)	6/35	0.47 (0.14–1.55)	0.32 (0.09–1.12)	15/115	0.68 (0.34–1.37)	0.66 (0.33–1.33)
> 6 to 9 months N = 150	9/60	0.93 (0.39–2.24)	0.99 (0.41–2.43)	11/68	0.45 (0.16–1.29)	0.26 (0.08–0.82)	20/137	0.77 (0.40–1.46)	0.76 (0.40–1.45)
> 9 months N = 131	9/39	1.41 (0.58–3.40)	1.39 (0.56–3.44)	8/75	0.30 (0.10–0.90)	0.18 (0.05–0.60)	18^†/120	0.78 (0.40–1.52)	0.74 (0.38–1.44)

CI, confidence interval; DVT, deep vein thrombosis; DOAC, direct oral anticoagulant; HR, hazard ratio; LMWH, low-molecular weight heparin; NPCR, National Prostate Cancer Register; NSAID, non-steroidal anti-inflammatory drug; PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism
^*Includes 73 men with VTE not specified as either DVT/PE, either ICD-10 I809 or I82)
^†Adjusted for age, time from prostate cancer to VTE diagnosis, and the following comorbidities before the index VTE: cardiovascular disease, hypertension, diabetes, major bleeding, cerebrovascular disease, and use of statins or NSAIDS before the index VTE
^†One case was classified as neither DVT or PE, but as 'other VTE'
Analysis included 510 men with VTE and at least 1 year of follow-up after the end of therapy). Anticoagulants included LMWH, VKAs and DOACs

ISSN: 1471-2490